To explore the role of G9a on radiotherapy of HNSCC, different concentrations of the specific G9a inhibitor BRD4770 were applied to treat Fadu and HN8 cells, and the IC50 value was calculated to be ~6 μM by CCK8 (Fig. S2C). This evidence concerns the gene EHMT2 and head and neck squamous cell carcinoma.